Clinical Trials

50 enrolled

Phase 1 Not yet recruiting

Colorectal Neoplasms

NCT07500298 2026-03-30

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

41 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT07491159 2026-03-24

Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study

106 enrolled

Colorectal Neoplasms

NCT04230187 2026-03-05

TRIBE-C

528 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Colorectal Neoplasms

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

100 enrolled

Phase 3 Active not recruiting

Colorectal Neoplasms

NCT05171660 2026-02-17

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

446 enrolled

Colorectal Neoplasms

NCT07407465 2026-02-17

CHIMERA

42 enrolled

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT04109924 2026-02-10

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Phase 2 Completed

42 enrolled 12 charts

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07395063 2026-02-09

A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.

68 enrolled

Colorectal Neoplasms

NCT04587128 2026-02-05

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

34 enrolled

Colorectal Neoplasms

NCT06268015 2026-02-05

BBOpCo

16 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT07389265 2026-02-05

CAPRI-3 GOIM

480 enrolled

Colorectal Neoplasms

NCT07381764 2026-02-02

ROMANCE - GOIM

150 enrolled

Colorectal Neoplasms

NCT07359456 2026-01-22

COLIBRI-GI

130 enrolled

Phase 4 Not yet recruiting

Colorectal Neoplasms

NCT07094893 2026-01-14

ARIEL-ENGIC

280 enrolled

Colorectal Neoplasms

NCT07337551 2026-01-13

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

20 enrolled

Colorectal Neoplasms

NCT04689347 2026-01-12

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

Phase 1/2 Recruiting

27 enrolled

Phase 1 Active not recruiting

Colorectal Neoplasms

NCT06838338 2026-01-08

JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

30 enrolled

Colorectal Neoplasms

NCT07229846 2026-01-08

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

30 enrolled

Colorectal Neoplasms

NCT06791512 2025-12-24

BASKETⅢ

166 enrolled

Colorectal Neoplasms

NCT06856837 2025-12-12

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

140 enrolled

Colorectal Neoplasms

NCT06245356 2025-12-10

TRIFLUOX-DP

73 enrolled

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT05843188 2025-12-09

Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer

155 enrolled

Phase 3 Not yet recruiting

Colorectal Neoplasms

NCT07271355 2025-12-09

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

129 enrolled

Appendiceal Neoplasms, Colorectal Neoplasms

NCT06733038 2025-12-08

AtezoTRIBE2

238 enrolled

Colorectal Neoplasms

NCT07261709 2025-12-03

Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial

236 enrolled

Colorectal Neoplasms

NCT07253896 2025-11-28

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

40 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT05627635 2025-11-10

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

20 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06784947 2025-10-02

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

13 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT02982694 2025-10-01

Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

Phase 2 Terminated

46 enrolled

Colorectal Neoplasms, Activated Protein C Resistance

NCT04595266 2025-09-29

LIVERPEARL

48 enrolled

Colorectal Neoplasms

NCT05678257 2025-09-12

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

Phase 2 Terminated

180 enrolled 16 charts

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT07150403 2025-09-08

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

74 enrolled

Colorectal Neoplasms

NCT07134101 2025-08-29

SMARTi-RC01

138 enrolled

Disease, Colorectal Neoplasms

NCT06887218 2025-08-27

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

57 enrolled

Colorectal Neoplasms

NCT06867822 2025-08-24

Trial of ProAgio in Advanced/Metastatic Colorectal Cancer

Phase 1 Recruiting

27 enrolled

Colorectal Neoplasms

NCT07123441 2025-08-14

A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer

300 enrolled

Colorectal Neoplasms

NCT07106034 2025-08-12

ONTOP

32 enrolled

Phase 3 Active not recruiting

Colorectal Neoplasms

NCT03828227 2025-07-18

COLAGE

49 enrolled

Colorectal Neoplasms

NCT07071844 2025-07-17

BETWEEN

162 enrolled

Neutropenia, Colorectal Neoplasms

NCT02885753 2025-07-09

OSCAR

348 enrolled

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT03186326 2025-06-29

SAMCO

Phase 2 Completed

132 enrolled

Colorectal Neoplasms

NCT00873275 2025-06-22

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Phase 1 Completed

11 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07021950 2025-06-15

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

130 enrolled

Colorectal Neoplasms

NCT07007728 2025-06-06

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

54 enrolled

Colorectal Neoplasms

NCT07009145 2025-06-06

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

22 enrolled

DermatologicGastrointestinalGenitourinaryThoracic

Colorectal Neoplasms

NCT06839105 2025-05-31

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Phase 1 Recruiting

214 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Colorectal Neoplasms

NCT06280495 2025-05-30

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Phase 2/3 Recruiting

156 enrolled

Colorectal Neoplasms

NCT06992648 2025-05-28

REGTAS-2

302 enrolled